A walk on the thoughtful “wild side” of why old-school epidemiology has over-promised and under-delivered, discovering that population density is more than how tightly we are packed, an alternative hypothesis for how sleep refreshes our bodies and spirits, and an update on a maligned energy source, fusion.  

"Recency bias" states that more recent memories come to mind more quickly. But specific ideas and objects that have “stood the test of time” can overcome recency bias. How do we take longevity into account when making judgments? Are old conserved ideas better than the novel? In the attention economy novel wins, but what about in our day-to-day lives?

Should Facebook be in the business of "debunking" news and scientific data when events are rapidly changing? What's true today may be declared false tomorrow, only to be declared true again a week later. Furthermore, does Facebook have the expertise to do so?

Are bald men more likely to get severe COVID-19? There are more than 30,000 news stories about this, almost all of which without question, accept the findings of a flawed epidemiological study from Spain. Is this a valid conclusion? Let's ask a biostatistician.

We have rightfully focused our nation’s health care attention on how best to manage the potentially deadly COVID-19 virus through treatment and/or prevention. The next few months will be telling, but we can now begin to focus on the future — one that may include new health care challenges given that fewer patients have been seeking preventative care or measures during the pandemic. ACSH friend Dr. Robert Popovian (pictured), VP of Pfizer's U.S. Government Relations, and colleague Dave Hering, regional president, North America for Pfizer Vaccines, discuss the challenges ahead.

Faced with a life-changing decision and a great deal of uncertainty, do patients prefer to decide for themselves after being given all the facts? Or do they prefer a nudge in “the right direction” by their physician?

Making life or death decisions has been brought into sharp relief by the COVID-19 pandemic. For the estimated 500,000 people on dialysis in the U.S., that is a bridge already crossed. Having chosen a life requiring continuous life support, do any of them have second thoughts?

Discredited journalist and conspiracy theorist Paul Thacker, who became infamous for spreading disinformation about GMOs and biotech scientists, is back. This time, he's ranting about 5G. But it seems he could only get his most recent work published in a foreign language with the help of a collaborator, Dutch journalist Jannes van Roermund.

From Washington DC to Washington's Puget Sound, from Chicago to North Carolina, Great Britain and even India, the American Council has been making its mark, bringing science-based reasoning to important conversations the world over. While COVID-19 has dominated the healthcare headlines, our experts weighed in on that essential subject as well as several others.

As an anti-coronavirus therapy, Remdesivir has been rather disappointing. That's primarily because the drug is given intravenously to those who are already very ill with COVID-19. But what would happen if the drug could be delivered directly to the lungs, to prevent severe disease? Gilead is giving it a shot. Here are some of the pros and cons of that approach.